These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
282 related articles for article (PubMed ID: 23225517)
1. Micro and nanoparticle-based delivery systems for vaccine immunotherapy: an immunological and materials perspective. Leleux J; Roy K Adv Healthc Mater; 2013 Jan; 2(1):72-94. PubMed ID: 23225517 [TBL] [Abstract][Full Text] [Related]
2. [Development of antituberculous drugs: current status and future prospects]. Tomioka H; Namba K Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921 [TBL] [Abstract][Full Text] [Related]
3. Engineering vaccines and niches for immune modulation. Purwada A; Roy K; Singh A Acta Biomater; 2014 Apr; 10(4):1728-40. PubMed ID: 24373907 [TBL] [Abstract][Full Text] [Related]
4. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines. Ruffini PA; Neelapu SS; Kwak LW; Biragyn A Haematologica; 2002 Sep; 87(9):989-1001. PubMed ID: 12217812 [TBL] [Abstract][Full Text] [Related]
5. Nano- and micro-encapsulated systems for enhancing the delivery of resveratrol. Augustin MA; Sanguansri L; Lockett T Ann N Y Acad Sci; 2013 Jul; 1290():107-12. PubMed ID: 23855472 [TBL] [Abstract][Full Text] [Related]
11. Status and future prospects of lipid-based particulate delivery systems as vaccine adjuvants and their combination with immunostimulators. Nordly P; Madsen HB; Nielsen HM; Foged C Expert Opin Drug Deliv; 2009 Jul; 6(7):657-72. PubMed ID: 19538037 [TBL] [Abstract][Full Text] [Related]
12. Administration routes affect the quality of immune responses: A cross-sectional evaluation of particulate antigen-delivery systems. Mohanan D; Slütter B; Henriksen-Lacey M; Jiskoot W; Bouwstra JA; Perrie Y; Kündig TM; Gander B; Johansen P J Control Release; 2010 Nov; 147(3):342-9. PubMed ID: 20727926 [TBL] [Abstract][Full Text] [Related]
13. Use of animal models in the development of human vaccines. Gerdts V; Littel-van den Hurk Sv; Griebel PJ; Babiuk LA Future Microbiol; 2007 Dec; 2(6):667-75. PubMed ID: 18041907 [TBL] [Abstract][Full Text] [Related]
14. Vaccine adjuvant systems: enhancing the efficacy of sub-unit protein antigens. Perrie Y; Mohammed AR; Kirby DJ; McNeil SE; Bramwell VW Int J Pharm; 2008 Dec; 364(2):272-80. PubMed ID: 18555624 [TBL] [Abstract][Full Text] [Related]
15. Targeting dendritic cells with nano-particulate PLGA cancer vaccine formulations. Hamdy S; Haddadi A; Hung RW; Lavasanifar A Adv Drug Deliv Rev; 2011 Sep; 63(10-11):943-55. PubMed ID: 21679733 [TBL] [Abstract][Full Text] [Related]
16. Nanotechnology-based manipulation of dendritic cells for enhanced immunotherapy strategies. Klippstein R; Pozo D Nanomedicine; 2010 Aug; 6(4):523-9. PubMed ID: 20085824 [TBL] [Abstract][Full Text] [Related]
18. Molecularly defined vaccines for cancer immunotherapy, and protective T cell immunity. Speiser DE; Romero P Semin Immunol; 2010 Jun; 22(3):144-54. PubMed ID: 20413326 [TBL] [Abstract][Full Text] [Related]
19. Targeting dendritic cells with biomaterials: developing the next generation of vaccines. Reddy ST; Swartz MA; Hubbell JA Trends Immunol; 2006 Dec; 27(12):573-9. PubMed ID: 17049307 [TBL] [Abstract][Full Text] [Related]